JP2021531273A5 - - Google Patents

Info

Publication number
JP2021531273A5
JP2021531273A5 JP2021502476A JP2021502476A JP2021531273A5 JP 2021531273 A5 JP2021531273 A5 JP 2021531273A5 JP 2021502476 A JP2021502476 A JP 2021502476A JP 2021502476 A JP2021502476 A JP 2021502476A JP 2021531273 A5 JP2021531273 A5 JP 2021531273A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
xrpd
solid form
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021502476A
Other languages
English (en)
Japanese (ja)
Other versions
JP7522720B2 (ja
JP2021531273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042226 external-priority patent/WO2020018680A1/en
Publication of JP2021531273A publication Critical patent/JP2021531273A/ja
Publication of JP2021531273A5 publication Critical patent/JP2021531273A5/ja
Priority to JP2024063946A priority Critical patent/JP2024083556A/ja
Application granted granted Critical
Publication of JP7522720B2 publication Critical patent/JP7522720B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021502476A 2018-07-18 2019-07-17 アゾロピリミジン化合物の固体形態 Active JP7522720B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063946A JP2024083556A (ja) 2018-07-18 2024-04-11 アゾロピリミジン化合物の固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862700064P 2018-07-18 2018-07-18
US62/700,064 2018-07-18
PCT/US2019/042226 WO2020018680A1 (en) 2018-07-18 2019-07-17 Solid forms of an azolopyrimidine compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063946A Division JP2024083556A (ja) 2018-07-18 2024-04-11 アゾロピリミジン化合物の固体形態

Publications (3)

Publication Number Publication Date
JP2021531273A JP2021531273A (ja) 2021-11-18
JP2021531273A5 true JP2021531273A5 (cg-RX-API-DMAC7.html) 2022-07-26
JP7522720B2 JP7522720B2 (ja) 2024-07-25

Family

ID=69164033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502476A Active JP7522720B2 (ja) 2018-07-18 2019-07-17 アゾロピリミジン化合物の固体形態
JP2024063946A Withdrawn JP2024083556A (ja) 2018-07-18 2024-04-11 アゾロピリミジン化合物の固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063946A Withdrawn JP2024083556A (ja) 2018-07-18 2024-04-11 アゾロピリミジン化合物の固体形態

Country Status (12)

Country Link
US (1) US11993584B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823614A4 (cg-RX-API-DMAC7.html)
JP (2) JP7522720B2 (cg-RX-API-DMAC7.html)
KR (1) KR102826213B1 (cg-RX-API-DMAC7.html)
CN (1) CN113015523B (cg-RX-API-DMAC7.html)
AU (1) AU2019306582B2 (cg-RX-API-DMAC7.html)
CA (1) CA3106366A1 (cg-RX-API-DMAC7.html)
MY (1) MY205549A (cg-RX-API-DMAC7.html)
PH (1) PH12021550084A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100267TA (cg-RX-API-DMAC7.html)
TW (1) TWI835821B (cg-RX-API-DMAC7.html)
WO (1) WO2020018680A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
BR112021022538A2 (pt) 2019-06-06 2021-12-28 Arcus Biosciences Inc Processos para preparar compostos de aminopirimidina
TW202421150A (zh) 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體
WO2024097736A1 (en) 2022-11-02 2024-05-10 Arcus Biosciences, Inc. Processes for preparing azolopyrimidine compounds
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474599A (en) 1982-07-14 1984-10-02 The Dow Chemical Company 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010077582A1 (en) * 2008-12-16 2010-07-08 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014048065A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
TWI641595B (zh) 2013-07-17 2018-11-21 日商大塚製藥股份有限公司 氰基三唑化合物類
MX389798B (es) * 2017-01-20 2025-03-20 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
BR112021022538A2 (pt) 2019-06-06 2021-12-28 Arcus Biosciences Inc Processos para preparar compostos de aminopirimidina

Similar Documents

Publication Publication Date Title
JP7861083B2 (ja) Fak阻害剤およびその併用薬物
JP2023530456A5 (cg-RX-API-DMAC7.html)
CA3016826C (en) Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof
JP2015509537A5 (cg-RX-API-DMAC7.html)
KR102731401B1 (ko) 키나아제 억제제로 사용되는 화합물 및 이의 응용
CN101878218A (zh) 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途
JP2016513704A5 (cg-RX-API-DMAC7.html)
JP2022507267A5 (cg-RX-API-DMAC7.html)
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
CA2862704C (en) Ribonucleotide reductase inhibitors and methods of use
JP2008528466A5 (cg-RX-API-DMAC7.html)
CN110396088A (zh) Hpk1激酶抑制剂、制备方法及其应用
JP2014524476A5 (cg-RX-API-DMAC7.html)
AU2022380979A1 (en) Pparg inverse agonists and uses thereof
JP2017507175A5 (cg-RX-API-DMAC7.html)
HRP20211151T1 (hr) Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama
JP2021513965A5 (cg-RX-API-DMAC7.html)
TW202412760A (zh) Cbl-b抑制劑及其使用方法
AU2006216266A2 (en) Quinazoline derivative having tyrosine kinase inhibitory activity
CN105254699B (zh) 4‑(4’‑三氟甲基)苯基‑2‑去氢表雄酮‑17’‑腙噻唑及其制备方法和用途
WO2007096618A2 (en) 2-[3h-thiazol-2-ylidinemethyl]pyridines and related compounds and their use
JP2023506066A (ja) 5-ブロモピリジン-3-イル-3-デオキシ-3-[4-(3,4,5-トリフルオロフェニル)-1h-1,2,3-トリアゾール-1-yl]-1-チオ-アルファ-d-ガラクトピラノシド及びその結晶形を調製するための大規模方法
JP2021522348A5 (cg-RX-API-DMAC7.html)
CN102133217B (zh) 一类以n为桥键的哒嗪酮类化合物在制备抗肿瘤的药物中的用途
CN113603713B (zh) 一种取代的硼酸酯化合物的制备方法及其晶型